Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paula Rodriguez-Otero

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Hemasphere|December 12, 2024
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experienceVeronica González-Calle, Paula Rodriguez-Otero, Maria J Calasanz, et al.
The Lancet. Oncology|June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma NetworkHeinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.
The Lancet. Oncology|May 31, 2024
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy CommitteeYi Lin, Lugui Qiu, Saad Usmani, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2021
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM ExperiencePaula Rodriguez-Otero, Maialen Sirvent, Ana Pilar González-Rodríguez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple MyelomaJuan-Jose Garcés, Maria-Teresa Cedena, Noemi Puig, et al.
American Journal of Hematology|November 16, 2024
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapyAintzane Zabaleta, Noemi Puig, Maria-Teresa Cedena, et al.
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
Nature Communications|June 23, 2026
Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment responseItziar Cenzano, Miguel Cócera, Marta Larrayoz, et al.
Transplantation and Cellular Therapy|March 20, 2022
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple MyelomaBinod Dhakal, Nina Shah, Ankit Kansagra, et al.
Nature Reviews. Clinical Oncology|July 7, 2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Hemasphere|December 12, 2024
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experienceVeronica González-Calle, Paula Rodriguez-Otero, Maria J Calasanz, et al.
The Lancet. Oncology|June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma NetworkHeinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.
The Lancet. Oncology|May 31, 2024
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy CommitteeYi Lin, Lugui Qiu, Saad Usmani, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2021
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM ExperiencePaula Rodriguez-Otero, Maialen Sirvent, Ana Pilar González-Rodríguez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple MyelomaJuan-Jose Garcés, Maria-Teresa Cedena, Noemi Puig, et al.
American Journal of Hematology|November 16, 2024
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapyAintzane Zabaleta, Noemi Puig, Maria-Teresa Cedena, et al.
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
Nature Communications|June 23, 2026
Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment responseItziar Cenzano, Miguel Cócera, Marta Larrayoz, et al.
Transplantation and Cellular Therapy|March 20, 2022
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple MyelomaBinod Dhakal, Nina Shah, Ankit Kansagra, et al.
Nature Reviews. Clinical Oncology|July 7, 2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Pageof 8